Skip to content

Evaluation of Safety and Tolerability of Purim Tablet in Healthy People

An Open-Label, Single-Arm Clinical Study to evaluate the Safety and Tolerability of Purim Tablet in Healthy Adultsâ??

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043510
Enrollment
12
Registered
2022-06-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy adult subjects of either sex aged between >=18 to 2. Subjects willing to sign informed consent and follow the study procedure. 3. Has not participated in a similar investigation in the past four weeks. 4. Subjects willing to refrain taking any other nutritional supplement during the study period

Exclusion criteria

Exclusion criteria: 1. Subjects with clinically significant serious cardiovascular, cerebrovascular, respiratory, liver, renal disease, congenital or any other disorder. 2. Subjects with any abnormal lab values detected at screening shall be excluded. 3. A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the investigational products (IP). 4. Pre-existing systemic disease necessitating long-term medications. 5. Genetic and endocrinal disorders. 6. Subjects who refused to sign informed consent. 7. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Occurrence of any adverse or serious adverse events during the study period.Timepoint: 7 days.

Secondary

MeasureTime frame
Overall compliance to the study medicationTimepoint: 7 days

Countries

India

Contacts

Public ContactKavitha R

Himalaya Wellness Company

dr.srikrishna@himalayawellness.com9731207312

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026